Navellier & Associates Inc Amgen Inc Transaction History

Navellier & Associates Inc

  • $805 Million
  • Q1 2024

A detailed history of Navellier & Associates Inc transactions in Amgen Inc stock. As of the latest transaction made, Navellier & Associates Inc holds 15,729 shares of AMGN stock, worth $4.91 Million. This represents 0.56% of its overall portfolio holdings.

Number of Shares
15,729
Previous 20,915 24.8%
Holding current value
$4.91 Million
Previous $6.02 Million 25.75%
% of portfolio
0.56%
Previous 0.91%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024
SELL
$268.87 - $324.56 $1.39 Million - $1.68 Million
-5,186 Reduced 24.8%
15,729 $4.47 Million
Q4 2023

Feb 08, 2024
BUY
$255.7 - $288.46 $268,740 - $303,171
1,051 Added 5.29%
20,915 $6.02 Million
Q3 2023

Nov 09, 2023
SELL
$218.65 - $271.46 $128,784 - $159,889
-589 Reduced 2.88%
19,864 $5.34 Million
Q2 2023

Aug 07, 2023
BUY
$214.27 - $253.37 $5,142 - $6,080
24 Added 0.12%
20,453 $4.54 Million
Q1 2023

May 12, 2023
SELL
$225.79 - $275.2 $82,187 - $100,172
-364 Reduced 1.75%
20,429 $4.94 Million
Q4 2022

Feb 02, 2023
BUY
$229.03 - $291.01 $287,432 - $365,217
1,255 Added 6.42%
20,793 $5.46 Million
Q3 2022

Nov 09, 2022
SELL
$224.46 - $253.15 $23,119 - $26,074
-103 Reduced 0.52%
19,538 $4.4 Million
Q2 2022

Aug 12, 2022
BUY
$230.71 - $256.74 $131,504 - $146,341
570 Added 2.99%
19,641 $4.78 Million
Q1 2022

Apr 29, 2022
BUY
$219.27 - $242.57 $148,007 - $163,734
675 Added 3.67%
19,071 $4.61 Million
Q4 2021

Feb 14, 2022
SELL
$198.88 - $227.6 $153,734 - $175,934
-773 Reduced 4.03%
18,396 $4.14 Million
Q3 2021

Oct 28, 2021
SELL
$212.27 - $248.7 $59,860 - $70,133
-282 Reduced 1.45%
19,169 $4.08 Million
Q2 2021

Aug 09, 2021
BUY
$233.58 - $259.14 $209,521 - $232,448
897 Added 4.83%
19,451 $4.74 Million
Q1 2021

May 12, 2021
SELL
$221.91 - $258.6 $43,716 - $50,944
-197 Reduced 1.05%
18,554 $4.62 Million
Q4 2020

Feb 05, 2021
SELL
$216.38 - $257.67 $139,565 - $166,197
-645 Reduced 3.33%
18,751 $4.31 Million
Q3 2020

Nov 09, 2020
SELL
$234.65 - $260.95 $77,903 - $86,635
-332 Reduced 1.68%
19,396 $4.93 Million
Q2 2020

Aug 12, 2020
SELL
$197.81 - $242.74 $66,464 - $81,560
-336 Reduced 1.67%
19,728 $4.65 Million
Q1 2020

May 13, 2020
SELL
$182.24 - $241.7 $144,698 - $191,909
-794 Reduced 3.81%
20,064 $4.07 Million
Q4 2019

Feb 12, 2020
SELL
$189.21 - $243.2 $111,633 - $143,488
-590 Reduced 2.75%
20,858 $5.03 Million
Q3 2019

Oct 16, 2019
BUY
$174.11 - $208.62 $79,220 - $94,922
455 Added 2.17%
21,448 $4.15 Million
Q2 2019

Jul 17, 2019
SELL
$166.7 - $195.41 $18,670 - $21,885
-112 Reduced 0.53%
20,993 $3.87 Million
Q1 2019

May 15, 2019
SELL
$180.87 - $203.88 $122,087 - $137,619
-675 Reduced 3.1%
21,105 $4.01 Million
Q4 2018

Jan 15, 2019
SELL
$178.4 - $208.25 $120,598 - $140,777
-676 Reduced 3.01%
21,780 $4.24 Million
Q3 2018

Nov 14, 2018
SELL
$185.29 - $208.89 $133,408 - $150,400
-720 Reduced 3.11%
22,456 $4.66 Million
Q2 2018

Aug 06, 2018
BUY
$166.05 - $186.51 $58,615 - $65,838
353 Added 1.55%
23,176 $4.28 Million
Q1 2018

May 21, 2018
BUY
$169.43 - $198.0 $104,538 - $122,166
617 Added 2.78%
22,823 $3.89 Million
Q4 2017

Feb 12, 2018
SELL
$168.79 - $188.59 $640,389 - $715,510
-3,794 Reduced 14.59%
22,206 $3.86 Million
Q3 2017

Nov 14, 2017
SELL
$167.29 - $191.0 $2.09 Million - $2.39 Million
-12,500 Reduced 32.47%
26,000 $4.85 Million
Q2 2017

Aug 24, 2017
BUY
N/A
38,500
38,500 $6.63 Million

Others Institutions Holding AMGN

# of Institutions
2,930
Shares Held
401M
Call Options Held
6.59M
Put Options Held
6.6M
View Full List

About AMGEN INC

AMGN Quotes by TradingView
  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $167B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Navellier & Associates Inc Portfolio

Follow Navellier & Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Navellier & Associates Inc, based on Form 13F filings with the SEC.

News

Stay updated on Navellier & Associates Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email